Pros and cons of catheter lock solutions

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 6, 2013, Pages 669-674

  Niyyar, Vandana D ^a   Lok, Charmaine E ^b  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

catheters; dysfunction; hemodialysis; lock solutions; vascular access

Indexed keywords

4 HYDROXYBENZOIC ACID ESTER; ALCOHOL; ALTEPLASE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CITRATE SODIUM; CITRATE TRISODIUM; EDETIC ACID; GENTAMICIN; HEPARIN; METHYLENE BLUE; TAUROLIDINE;

ANTIMICROBIAL ACTIVITY; BACTEREMIA; BIOFILM; BLEEDING; CATHETER INFECTION; CATHETER RELATED BACTEREMIA; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM INJURY; HEART ARRHYTHMIA; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFECTION RISK; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS (TOPIC); METALLIC TASTE; MULTICENTER STUDY (TOPIC); ORAL PARESTHESIA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCANNING ELECTRON MICROSCOPY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CITRIC ACID; ETHANOL; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; RENAL DIALYSIS; SOLUTIONS; VASCULAR ACCESS DEVICES;

EID: 84887018433     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328365ba53     Document Type: Review

References (68)

1. Diskin CJ, Stokes TJ, Panus LW. The importance of delay in cannulation after hemodialysis vascular access surgery. Nephron 1996; 74:245-249.
2. CORR. http://www.cihi.ca/CIHI-ext-portal/pdf/internet/SERVICES-CORR- PIACORR-EN. Ottawa, Ontario, Canada: Canadian Institute of Health Information; 2012. [Accessed 13 February 2013]
3. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 1999; 34:1114-1124.
4. Beathard GA. Dysfunction of new catheters by old fibrin sheaths. Semin Dial 2004; 17:243-244.
5. Oliver MJ, Mendelssohn DC, Quinn RR, et al. Catheter patency and function after catheter sheath disruption: a pilot study. Clin J Am Soc Nephrol 2007; 2:1201-1206.
6. Bregman H. Double lumen subclavian hemodialysis cannulas. Int J Artif Organs 1985; 8:17-18.
7. Snider HC, Ingalls CE, Schloeder FX, Sivanna P. Use of subclavian catheters for hemodialysis. South Med J 1982; 75:1093-1094.
8. Uldall R. The subclavian catheter in haemodialysis. Proc Eur Dial Transplant Assoc 1983; 19:106-114.
9. Ash SR. Fluid mechanics and clinical success of central venous catheters for dialysis: answers to simple but persisting problems. Semin Dial 2007; 20:237-256.
10. Ash SR. Advances in tunneled central venous catheters for dialysis: design and performance. Semin Dial 2008; 21:504-515.
11. Niyyar VD. Catheter dysfunction: the role of lock solutions. Semin Dial 2012; 25:693-699
12. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33:1387-1392.
13. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol 2005; 13:34-40.
14. Mehall JR, Saltzman DA, Jackson RJ, Smith SD. Fibrin sheath enhances central venous catheter infection. Crit Care Med 2002; 30:908-912.
15. van Rooden CJ, Schippers EF, Barge RM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23:2655-2660.
16. Dasgupta MK. Biofilms and infection in dialysis patients. Semin Dial 2002; 15:338-346.
17. Hirsh J, Anand SS, Halperin JL, Fuster V. AHA scientific statement: guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vasc Biol 2001; 21:E9.
18. Sungur M, Eryuksel E, Yavas S, et al. Exit of catheter lock solutions from double lumen acute haemodialysis catheters: an in vitro study. Nephrol Dial Transplant 2007; 22:3533-3537.
19. Karaaslan H, Peyronnet P, Benevent D, et al. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant 2001; 16:2072-2074.
20. Yevzlin AS, Sanchez RJ, Hiatt JG, et al. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Semin Dial 2007; 20:351-354.
21. Thomas CM, Zhang J, Lim TH, et al. Concentration of heparin-locking solution and risk of central venous hemodialysis catheter malfunction. ASAIO J 2007; 53:485-488.
22. Holley JL, Bailey S. Catheter lock heparin concentration: effects on tissue plasminogen activator use in tunneled cuffed catheters. Hemodial Int 2007; 11:96-98.
23. Ivan DM, Smith T, Allon M. Does the heparin lock concentration affect hemodialysis catheter patency? Clin J Am Soc Nephrol 2010; 5:1458-1462.
24. Shanks RM, Sargent JL, Martinez RM, et al. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 2006; 21:2247-2255.
25. Shanks RM, Donegan NP, Graber ML, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005; 73:4596-4606.
26. Moran JE, Ash SR. Locking solutions for hemodialysis catheters; heparin and citrate-a position paper by ASDIN. Semin Dial 2008; 21:490-492.
27. Macrae JM, Dojcinovic I, Djurdjev O, et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clin J Am Soc Nephrol 2008; 3:369-374.
28. Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters: an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 2007; 22:471-476.
29. Lok CE, Appleton D, Bhola C, et al. Trisodium citrate 4%: an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 2007; 22:477-483.
30. Buturovic J, Ponikvar R, Kandus A, et al. Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artif Organs 1998; 22:945-947.
31. Bevilacqua JL, Gomes JG, Santos VF, Canziani ME. Comparison of trisodium citrate and heparin as catheter-locking solution in hemodialysis patients. J Bras Nefrol 2011; 33:86-92.
32. Yon CK, Low CL. Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters. Am J Health Syst Pharm 2013; 70:131-136.
33. Weijmer MC, van den Dorpel MA, Van de Ven PJ, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 2005; 16:2769-2777.
34. Polaschegg HD, Sodemann K. Risks related to catheter locking solutions containing concentrated citrate. Nephrol Dial Transplant 2003; 18:2688-2690.
35. Power A, Duncan N, Singh SK, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis 2009; 53:1034-1041.
36. Schilcher G, Scharnagl H, Horina JH, et al. Trisodium citrate induced protein precipitation in haemodialysis catheters might cause pulmonary embolism. Nephrol Dial Transplant 2012; 27:2953-2957.
37. Willicombe MK, Vernon K, Davenport A. Embolic complications from central venous hemodialysis catheters used with hypertonic citrate locking solution. Am J Kidney Dis 2010; 55:348-351.
38. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 2002; 17:2189-2195.
39. Jones SM, Ravani P, Hemmelgarn BR, et al. Morphometric and biological characterization of biofilm in tunneled hemodialysis catheters. Am J Kidney Dis 2011; 57:449-455.
40. Bosma JW, Siegert CE, Peerbooms PG, Weijmer MC. Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial. Nephrol Dial Transplant 2010; 25:1213-1217.
41. Stranz M, Hadaway L. Risk of bacterial contamination from citrate catheter locks. Semin Dial 2009; 22:704.
42. Hemmelgarn BR, Moist LM, Lok CE, et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 2011; 364:303-312.
43. Daisy Kosa S, Lok CE. The economics of hemodialysis catheter-related infection prophylaxis. Semin Dial 2013; 26:482-493.
44. Shenep LE, Shenep MA, Cheatham W, et al. Efficacy of intravascular catheter lock solutions containing preservatives in the prevention of microbial colonization. J Hosp Infect 2011; 79:317-322.
45. Sanders J, Pithie A, Ganly P, et al. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother 2008; 62: 809-815.
46. Kayton ML, Garmey EG, Ishill NM, et al. Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections. J Pediatr Surg 2010; 45:1961-1966.
47. Guenu S, Heng AE, Charbonne F, et al. Mass spectrometry and scanning electron microscopy study of silicone tunneled dialysis catheter integrity after an exposure of 15 days to 60% ethanol solution. Rapid Commun Mass Spectrom 2007; 21:229-236.
48. Bell AL, Gu X, Burczynski FJ, Vercaigne LM. Ethanol/trisodium citrate for hemodialysis catheter lock. Clin Nephrol 2004; 62:369-373.
49. Bell AL, Jayaraman R, Vercaigne LM. Effect of ethanol/trisodium citrate lock on the mechanical properties of carbothane hemodialysis catheters. Clinical nephrology 2006; 65:342-348.
50. Broom JK, O'Shea S, Govindarajulu S, et al. Rationale and design of the HEALTHY-CATH trial: a randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients. BMC Nephrol 2009; 10:23.
51. Zwiech R, Adelt M, Chrul S. A taurolidine-citrate-heparin lock solution effectively eradicates pathogens from the catheter biofilm in hemodialysis patients. Am J Ther 2013. [Epub ahead of print]
52. Solomon LR, Cheesbrough JS, Ebah L, et al. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am J Kidney Dis 2010; 55:1060-1068.
53. Solomon LR, Cheesbrough JS, Bhargava R, et al. Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidinecitrate- heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis. Semin Dial 2012; 25:233-238.
54. Moran J, Sun S, Khababa I, et al. A randomized trial comparing gentamicin/ citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. Am J Kidney Dis 2012; 59:102-107.
55. Landry DL, Braden GL, Gobeille SL, et al. Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 2010; 5:1799-1804.
56. Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13:2133-2139.
57. Sofroniadou S, Revela I, Smirloglou D, et al. Linezolid versus vancomycin antibiotic lock solution for the prevention of nontunneled catheter-related blood stream infections in hemodialysis patients: a prospective randomized study. Semin Dial 2012; 25:344-350.
58. Kim SH, Song KI, Chang JW, et al. Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: a prospective, randomized clinical trial. Kidney Int 2006; 69:161-164.
59. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 2004; 66:801-805.
60. Nori US, Manoharan A, Yee J, Besarab A. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am J Kidney Dis 2006; 48:596-605.
61. Saxena AK, Panhotra BR, Sundaram DS, et al. Enhancing the survival of tunneled haemodialysis catheters using an antibiotic lock in the elderly: a randomised, double-blind clinical trial. Nephrology (Carlton) 2006; 11:299-305.
62. Campos RP, do Nascimento MM, Chula DC, Riella MC. Minocycline-EDTA lock solution prevents catheter-related bacteremia in hemodialysis. J Am Soc Nephrol 2011; 22:1939-1945
63. Bleyer AJ, Mason L, Russell G, et al. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infect Control Hosp Epidemiol 2005; 26:520-524.
64. Allon M. Prophylaxis against dialysis catheter-related bacteremia: a glimmer of hope. Am J Kidney Dis 2008; 51:165-168.
65. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2011; 39 (4 Suppl 1):S1-S34.
66. Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. Nephrol Dial Transplant 2008; 23:1666-1672.
67. Steczko J, Ash SR, Nivens DE, et al. Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/ parabens). Nephrol Dial Transplant 2009; 24:1937-1945.
68. Maki DG, Ash SR, Winger RK, Lavin P. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multicenter, controlled, randomized trial. Crit Care Med 2011; 39:613-620.